Cat: IPD-X11549

Recombinant Human ACVR2B Protein, N- His-B2M

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • 基因名

    ACVR2B

  • Application

    SPRMSTBLIITCELISA细胞实验药物筛选

  • 别名

    Activin receptor type IIB Short name: ACTR-IIB

  • 种属

    Human

  • 表达系统

    E. coli

  • 标签

    N- His-B2M

  • 纯度

    Greater than 85% as determined by SDS-PAGE.

  • 蛋白编号

    Q13705

  • 表达区间

    19-137aa

  • 蛋白长度

    Partial

  • 分子量

    27.7

  • 内毒素

    < 1.0 EU per μg protein as determined by the LAL method.

  • 性状

    Freeze-dried powder

  • 缓冲液

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • 复溶方法

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • 个性化定制

    点位突变 标签定制 buffer定制 全长蛋白定制

  • 稳定性测试

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • 保存条件 & 期限

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • 运输条件

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

ACVR2B, or Activin A receptor type IIB, is a member of the transforming growth factor-beta (TGF-β) superfamily of receptors, which plays a critical role in various biological processes, including muscle growth, development, and inflammation. In recent years, research has focused on the therapeutic potential of ACVR2B modulation, particularly in the context of muscle wasting diseases and age-related sarcopenia. Studies have shown that the inhibition of ACVR2B signaling can lead to increased muscle mass and improved functional outcomes, making it a promising target for interventions aimed at counteracting muscle degeneration. Scientists have developed recombinant proteins, such as ACVR2B-Fc fusion proteins, to block the receptor's activity, thus promoting muscle hypertrophy and enhancing physical performance. Additionally, ACVR2B's involvement in metabolic regulation and its interactions with other signaling pathways underscore its importance in health and disease. The ongoing exploration of ACVR2B-focused therapies is paving the way for innovative approaches to treat conditions characterized by muscle loss and to improve the overall quality of life in aging populations or individuals with chronic illnesses.

客服热线

027-8586 6806

E-mail

sales@ipodix.cn

人工客服①

汪经理

18007124176


加微信咨询

人工客服②

简经理

18164034885


加微信咨询
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
  • 30000+

    Recombinant

  • 100+

    Researcher

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US